BIOMAT Database Logo BIOMAT Database Logo

News from the FDA Cardio-renal Advisory Committee meeting of June 26, 1997. 1997

B M Massie

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D014486 United States Food and Drug Administration An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc. Food and Drug Administration (U.S.),USFDA,Food and Drug Administration,United States Food, Drug Administration
D017277 Drug Approval Process that is gone through in order for a drug to receive approval by a government regulatory agency. This includes any required pre-clinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance of the drug. Drug Approval Process,New Drug Approval,Food and Drug Administration Drug Approval,Food and Drug Administration Drug Approval Process,New Drug Approval Process,Approval Process, Drug,Approval Processes, Drug,Approval, Drug,Approval, New Drug,Approvals, Drug,Approvals, New Drug,Drug Approval Processes,Drug Approval, New,Drug Approvals,Drug Approvals, New,New Drug Approvals,Process, Drug Approval,Processes, Drug Approval
D017984 Enoxaparin Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) Clexane,EMT-966,EMT-967,Enoxaparine,Lovenox,PK-10,169,PK-10169,EMT 966,EMT 967,EMT966,EMT967,PK 10,169,PK 10169,PK10,169,PK10169
D018818 Fenoldopam A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation. Corlopam,Fenoldopam Hydrobromide,Fenoldopam Mesylate,SK&F-82526,SK&F-82526J,SKF-82526,SKF-82526J,Hydrobromide, Fenoldopam,SK&F 82526,SK&F 82526J,SK&F82526,SK&F82526J,SKF 82526,SKF 82526J,SKF82526,SKF82526J

Related Publications

B M Massie
FDA Arthritis Advisory Committee meeting.
September 1982, Arthritis and rheumatism,
B M Massie
FDA Arthritis Advisory Committee meeting.
May 1982, Arthritis and rheumatism,
B M Massie
FDA advisory committee meeting outcomes.
June 2012, Nature reviews. Drug discovery,
B M Massie
FDA Arthritis Advisory Committee Meeting.
October 1983, Arthritis and rheumatism,
B M Massie
The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
August 2007, The New England journal of medicine,
B M Massie
Government affairs. FDA Arthritis Advisory Committee Meeting.
November 1983, Arthritis and rheumatism,
B M Massie
Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
January 2011, Journal of the American Society of Nephrology : JASN,
B M Massie
Meeting of the Global Advisory Committee on Vaccine Safety,June 2011.
July 2011, Releve epidemiologique hebdomadaire,
B M Massie
FDA advisory committee meeting on prasugrel for acute coronary syndromes.
March 2009, P & T : a peer-reviewed journal for formulary management,
B M Massie
FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs.
October 1985, Arthritis and rheumatism,
Copied contents to your clipboard!